作者
Rachel A. Freedman,Hillary Heiling,T. Li,Dario Trapani,Nabihah Tayob,Karen L. Smith,Robert K. Davis,Alyssa Pereslete,Michelle K. DeMeo,Caitlin Cotter,W. Y. Chen,Heather A. Parsons,Cesar A. Santa-Maria,Catherine Van Poznak,Beverly Moy,Adam Brufsky,M. Melisko,Ciara C. O’Sullivan,Nadia Ashai,Yasmeen Rauf,J R Nangia,Robert T. Burns,J. Savoie,Antonio C. Wolff,E.P. Winer,M.F. Rimawi,I.E. Krop,Nai-Lu Lin
摘要
Treatment options for HER2-positive breast cancer brain metastases (BCBM) remain limited. We previously reported central nervous system (CNS) activity for neratinib and neratinib-capecitabine. Preclinical data suggest that neratinib may overcome resistance to ado-trastuzumab-emtansine (T-DM1) when given in combination. In TBCRC 022's cohort 4, we examined the efficacy of neratinib plus T-DM1 in patients with HER2-positive BCBM.